ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

INBS vs SNOA // EV/EBITDA & P/E VALUATION

Intelligent Bio Solutions Inc. (NASDAQ) VS. Sonoma Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: INBS 3 — SNOA 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INBS VS. SNOA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC INBS SNOA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 40.80% 38.00% +2.80 INBS /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -12.60% -47.40 SNOA /operating-margins <GO>
Net Profit Margin -60.00% 0.00% -60.00 SNOA /net-margins <GO>
Revenue Growth (YoY) -1.90% 36.70% -38.60 SNOA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 4/9 -1.00 SNOA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.2 39.8 +13.43 INBS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $6.1M $5.7M $323.6K INBS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR INBS REV SNOA REV INBS GROSS % SNOA GROSS % INBS FCF SNOA FCF
FY 2025 $3.1M $19.5M 40.8% 38.0% -$9.9M -$4.1M
FY 2024 $3.1M $14.3M 45.8% 38.2% -$9.8M -$168.0K
FY 2023 $1.3M $12.7M — — -$7.4M -$2.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INBS // BETA —
SNOA // BETA —